![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() by AFP Staff Writers Washington (AFP) Sept 8, 2022
A US judge ruled Wednesday in favor of Christian employers who refuse, on religious grounds, to provide workers with health insurance that covers the cost of drugs that help prevent HIV/AIDS. District Judge Reed O'Connor of a Texas federal court, known for making several rulings hostile to former president Barack Obama's sweeping health care law, took aim at a new aspect of the legislation nicknamed Obamacare. The law requires private insurers to reimburse certain preventive care as defined by health authorities. In 2020, they included PrEP -- pills that act to prevent HIV transmission. Two companies and several individuals went to court to challenge the coverage of the drugs, saying it violates their religious beliefs by making them "complicit in facilitating homosexual behavior," O'Connor said in his decision. One of the plaintiffs was facing fines of $100 per employee per day for failing to comply with the Obamacare law, said the judge, who ruled that the requirement to reimburse the cost of PrEP pills violates the federal Religious Freedom Restoration Act. President Joe Biden's Democratic administration will likely appeal the ruling. "The administration is reviewing today's decision by the Northern District of Texas," White House Press Secretary Karine Jean-Pierre said on Twitter, noting that the Affordable Care Act "has been the law of the land for over 10 years." The Texas decision was strongly criticized by the Speaker of the House of Representatives, Nancy Pelosi. "This disturbing decision amounts to open homophobia," Pelosi, a Biden ally, said in a statement. PrEP, short for pre-exposure prophylaxis, was approved by the US Food and Drug Administration in 2012 and is now routinely recommended for high-risk people who are HIV-negative to prevent them from becoming infected. When taken daily, PrEP reduces the risk of infection by 99 percent, but only 23 percent of people who could benefit from it were using the medicine in 2019.
![]() ![]() China's Chengdu extends Covid lockdown Beijing (AFP) Sept 8, 2022 The Chinese megacity of Chengdu has extended a Covid-19 lockdown in most areas, maintaining curbs that have ground business to a halt and confined the majority of its 21 million residents to their homes. China is the last major economy welded to a zero-Covid strategy, tamping down virus flare-ups through a combination of snap lockdowns, mass testing and lengthy quarantines. Chengdu, the capital of southwestern Sichuan province, has been effectively under lockdown for a week since reporting sever ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |